Access the full text.
Sign up today, get DeepDyve free for 14 days.
I. Tough, A. Baikie, D. Harnden, MargaretJ. King, W. BROWN, KarinE. Buckton, P. Jacobs, J. McBride (1961)
Cytogenetic studies in chronic myeloid leukaemia and acute leukaemia associated with monogolism.Lancet, 1 7174
C. Verfaillie, R. Hurley, B. Lundell, C. Zhao, R. Bhatia (1997)
Integrin-mediated regulation of hematopoiesis: do BCR/ABL-induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors?Acta haematologica, 97 1-2
T. Lugo, A. Pendergast, A. Muller, O. Witte (1990)
Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.Science, 247 4946
E. Weisberg, J. Griffin (2000)
Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines.Blood, 95 11
D. Porter, J. Antin (1999)
The graft-versus-leukemia effects of allogeneic cell therapy.Annual review of medicine, 50
P. Nowell, J. Finan, Jonni Moore, Laird Jackson, Arthur Weiss (1989)
Ph-negative T cells in a patient with chronic myelogenous leukemia for twenty-eight years.Leukemia research, 13 11
H. Odai, K. Sasaki, Akihiro Iwamatsu, Tetsuya Nakamoto, H. Ueno, Tetsuya Yamagata, K. Mitani, Yoshio Yazaki, Hisamaru Hirai (1997)
Purification and molecular cloning of SH2- and SH3-containing inositol polyphosphate-5-phosphatase, which is involved in the signaling pathway of granulocyte-macrophage colony-stimulating factor, erythropoietin, and Bcr-Abl.Blood, 89 8
P. Nowell, C. Croce (1990)
Philip Levine award lecture. Chromosome translocations and oncogenes in human lymphoid tumors.American journal of clinical pathology, 94 2
Y. Tsujimoto, L. Finger, J. Yunis, P. Nowell, C. Croce (1984)
Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation.Science, 226 4678
P. Fialkow, P. Martin, V. Najfeld, G. Penfold, R. Jacobson, J. Hansen (1981)
Evidence for a multistep pathogenesis of chronic myelogenous leukemia.Blood, 58 1
P. Nowell, D. Hungerford (1960)
Chromosome studies on normal and leukemic human leukocytes.Journal of the National Cancer Institute, 25
Rowley Jd (1980)
Ph1-positive leukaemia, including chronic myelogenous leukaemia.Clinics in haematology, 9
I. Cunningham, T. Gee, M. Dowling, R. Chaganti, R. Bailey, S. Hopfan, L. Bowden, A. Turnbull, W. Knapper, B. Clarkson (1979)
Results of treatment of Ph'+ chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol).Blood, 53 3
J. Apperley (1998)
Hematopoietic stem cell transplantation in chronic myeloid leukemia.Current opinion in hematology, 5 6
P. Nowell (1976)
The clonal evolution of tumor cell populations.Science, 194 4260
A. Cuneo, R. Bigoni, B. Emmanuel, E. Smit, G. Rigolin, M. Roberti, A. Bardi, N. Piva, G. Scapoli, G. Castoldi, H. Berghe, A. Hagemeijer (1998)
Fluorescence in situ hybridization for the detection and monitoring of the Ph-positive clone in chronic myelogenous leukemia: comparison with metaphase banding analysisLeukemia, 12
N. Takeda, M. Shibuya, Y. Maru (1999)
The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein.Proceedings of the National Academy of Sciences of the United States of America, 96 1
E. Feinstein, G. Cimino, R. Gale, G. Alimena, R. Berthier, K. Kishi, J. Goldman, A. Zaccaria, A. Berrebi, E. Canaani (1991)
p53 in chronic myelogenous leukemia in acute phase.Proceedings of the National Academy of Sciences of the United States of America, 88 14
D. Hockenbery, G. Núñez, C. Milliman, R. Schreiber, S. Korsmeyer (1990)
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell deathNature, 348
P. Nowell, L. Cole, M. Ellis (1956)
Induction of intestinal carcinoma in the mouse by whole-body fast-neutron irradiation.Cancer research, 16 9
B. Druker, S. Tamura, E. Buchdunger, S. Ohno, G. Segal, S. Fanning, J. Zimmermann, N. Lydon (1996)
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cellsNature Medicine, 2
P. Nowell, Lisa Moreau, Patrick Growney, Emmanuel Besa (1988)
Karyotypic stability in chronic B-cell leukemia.Cancer genetics and cytogenetics, 33 2
P. Nowell, L. Cole, J. Habermeyer, P. Roan (1956)
Growth and continued function of rat marrow cells in x-radiated mice.Cancer research, 16 3
P. Nowell, D. Hungerford, P. Nowell (1960)
A minute chromosome in human chronic granulocytic leukemiaScience, 132
R. Kronenwett, R. Haas (1998)
Specific bcr-abl-directed antisense nucleic acids and ribozymes: a tool for the treatment of chronic myelogenous leukemia?Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 144
H. Nakai, S. Misawa (1995)
Chromosome 17 abnormalities and inactivation of the p53 gene in chronic myeloid leukemia and their prognostic significance.Leukemia & lymphoma, 19 3-4
K. Shuai, J. Halpern, J. Hoeve, X. Rao, C. Sawyers (1996)
Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.Oncogene, 13 2
D. Lane (1968)
Chronic myelocytic leukemiaThe Journal of Pediatrics, 73
R. Silver, S. Woolf, R. Hehlmann, F. Appelbaum, J. Anderson, Charles Bennett, J. Goldman, F. Guilhot, H. Kantarjian, A. Lichtin, M. Talpaz, S. Tura (1999)
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.Blood, 94 5
M. Nitta, Y. Kato, A. Strife, M. Wachter, Jerrold Fried, Amaury Perez, Suresh Jhanwar, R. Osterndorf, R. Chaganti, Bayard Clarkson (1985)
Incidence of involvement of the B and T lymphocyte lineages in chronic myelogenous leukemia.Blood, 66 5
E. Osgood, M. Krippaehne (1955)
The gradient tissue culture method.Experimental cell research, 9 1
I. Sánchez-García, G. Grütz (1995)
Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2.Proceedings of the National Academy of Sciences of the United States of America, 92 12
L. Cole, P. Nowell (1965)
Radiation carcinogenesis: the sequence of events.Science, 150 3705
(2000)
Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-a therapy or allogeneic bone marrow transplantation
L. Chan, K. Karhi, S. Rayter, N. Heisterkamp, S. Eridani, R. Powle, S. Lawler, J. Groffen, J. Foulkes, M. Greaves, L. Wiedemann (1987)
A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia positive acute lymphoblastic leukaemiaNature, 325
A. Gewirtz, D. Sokol, M. Ratajczak (1998)
Nucleic acid therapeutics: state of the art and future prospects.Blood, 92 3
C. Sawyers, J. McLaughlin, O. Witte (1995)
Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogeneThe Journal of Experimental Medicine, 181
J. Groffen, J. Stephenson, N. Heisterkamp, A. Klein, C. Bartram, G. Grosveld (1984)
Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22Cell, 36
S. Faderl, M. Talpaz, Z. Estrov, H. Kantarjian (1999)
Chronic Myelogenous Leukemia: Biology and TherapyAnnals of Internal Medicine, 131
R. Kurzrock, M. Shtalrid, P. Romero, W. Kloetzer, Moshe Talpas, J. Trujillo, M. Blick, M. Beran, J. Gutterman (1987)
A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemiaNature, 325
C. Biernaux, M. Loos, A. Sels, G. Huez, P. Stryckmans (1995)
Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals.Blood, 86 8
J. Rowley (1973)
A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa StainingNature, 243
▪▪ Abstract Our understanding and treatment of chronic myelogenous leukemia (CML) has progressed since 1960 in parallel with work on cancer in general. CML provided the first evidence of a specific genetic change associated with a human cancer (the Philadelphia chromosome) and the clonal nature of these disorders. With improved cytogenetic and molecular techniques over subsequent decades, the specific genetic rearrangements of CML and many other tumors were defined and the complex mechanisms of carcinogenesis gradually unraveled. During this period, improved treatments for CML (chemotherapy, interferon, bone marrow transplantation) were implemented, and therapy targeted to the specific genetic change in the leukemic cells has recently been brought to promising clinical trials. Similar efforts are under way for other human cancers, and although the problem is enormously complex, there is real hope for major improvements in controlling these disorders.
Annual Review of Medicine – Annual Reviews
Published: Feb 1, 2002
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.